Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study

Trial Profile

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Cycloserine/lurasidone (Primary) ; Ketamine; Lurasidone
  • Indications Bipolar depression; Suicidal ideation
  • Focus Registrational; Therapeutic Use
  • Acronyms SBD-ASIB
  • Sponsors NeuroRX
  • Most Recent Events

    • 29 Nov 2018 Planned End Date changed from 31 Mar 2019 to 31 Mar 2020.
    • 29 Nov 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Dec 2019.
    • 29 Nov 2018 Planned initiation date changed from 1 May 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top